WHO vaccine experts say that an interim analysis of clinical trial data from two Chinese Covid-19 vaccines showed they demonstrated “safety and good efficacy,” but that more data was needed.
The Chinese firms Sinovac and Sinopharm, whose Covid shots are already being used in several countries, have submitted data in applications for the World Health Organization’s emergency use listing (EUL) green light.
The UN health agency’s Strategic Advisory Group of Experts on Immunization (SAGE) says it had reviewed the data provided so far, and that both vaccines “demonstrated safety and good efficacy against symptomatic Covid-19 disease.”
However, it warns, “both vaccines lacked data in older age groups and in persons with co-morbidities,” meaning other medical conditions.
“Post-introduction vaccine effectiveness and safety studies will be needed to address the impact on those sub-populations,” SAGE says in a list of highlights published after a meeting last week to discuss developments on vaccines against a range of diseases.
The two vaccines are among four homegrown ones that have been approved by Chinese regulators so far, but SAGE pointed out that neither had yet received authorization by what the WHO considers “a stringent regulatory authority.”
Your next read: ToI Editors' Picks
LIMITED TIME OFFER: Join The Times of Israel Community today and you'll receive a physical book of your choice, carefully curated by our editors.
Choose between two must-reads: When We See You Again by Rachel Goldberg-Polin, a searing portrait of a mother’s grief and strength following unthinkable tragedy;
Or Out of the Sky: Heroism and Rebirth in Nazi Europe by Matti Friedman, the gripping and surprising tale of a forgotten moment during World War II.
As a Community member, you’ll also enjoy our DocuNation series of outstanding Israeli documentary films, an ad-free experience of our site and podcasts, commenting privileges, and more.
CHOOSE YOUR BOOK
CHOOSE YOUR BOOK
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this